We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.
- Authors
Le Calvez, Baptiste; Tessoullin, Benoit; Renaud, Loïc; Botella-Garcia, Carmen; Srour, Micha; Le Gouill, Steven; Guillerm, Gaelle; Gressin, Rémy; Nguyen Quoc, Stéphanie; Furst, Sabine; Chauchet, Adrien; Sibon, David; Lewalle, Philippe; Poiré, Xavier; Maillard, Natacha; Villate, Alban; Loschi, Michael; Paillassa, Jérôme; Beguin, Yves; Dulery, Rémy
- Abstract
Background: Despite therapeutic progress, 10 to 30% of adult patients with primary mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse (R/R). Allogeneic stem cell transplantation (allo-HSCT) thus remains a potentially curative option in this setting. Material and Methods: In this multicenter retrospective study, the outcomes of 33 French and Belgian adult patients allo-transplanted for R/R PMBCL between January 1999 and December 2018, were examined. Results: At allo-HSCT time, patients had received a median of 3 treatment lines, 50% of them were in complete response, 40% in partial response and 10% had a progressive disease. Forty-two percent of the donors were siblings and 39% matched related. The median follow-up for alive patients was 78 months (3.5–157). Considering the whole cohort, 2-year overall survival (OS), progression free survival (PFS) and graft-versus-host disease-free/relapse-free survival (GRFS) were 48% (95%CI: 33–70), 47% (95%CI: 33–68) and 38.5% (95%CI: 25–60) respectively. Cumulative incidence of relapse and non-relapse mortality rates were respectively 34% (95%CI: 18–50) and 18% (95%CI: 7–34). Disease status at transplant was the only factor predicting survivals, patients with progressive disease showing significant lower 2-year PFS (HR: 6.12, 95%CI: 1.32–28.31, p = 0.02) and OS (HR: 7.04, 95%CI: 1.52–32.75, p = 0.013). A plateau was observed for OS and PFS after 4 years with 10 patients alive after this date, suggesting that almost one third of the patients effectively salvaged and undergoing allo-SCT could be cured. Conclusion: This study indicates that allo-HSCT is a valid therapeutic option for R/R PMBCL, providing durable remissions.
- Subjects
BELGIUM; FRANCE; RESEARCH; HOMOGRAFTS; CONFIDENCE intervals; GRAFT versus host disease; B cell lymphoma; RETROSPECTIVE studies; DISEASE incidence; MEDIASTINAL tumors; TREATMENT effectiveness; DESCRIPTIVE statistics; HEMATOPOIETIC stem cell transplantation; PROGRESSION-free survival; PROPORTIONAL hazards models; ADULTS
- Publication
Acta Oncologica, 2022, Vol 61, Issue 11, p1332
- ISSN
0284-186X
- Publication type
Article
- DOI
10.1080/0284186X.2022.2130709